|
License Agreements - Additional Information (Detail)
|
0 Months Ended | 12 Months Ended | 90 Months Ended | 0 Months Ended | 12 Months Ended | 1 Months Ended | 3 Months Ended | 12 Months Ended | 1 Months Ended | 3 Months Ended | 12 Months Ended | 12 Months Ended | 0 Months Ended | 12 Months Ended | 1 Months Ended | 12 Months Ended | 1 Months Ended | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Jan. 07, 2011
USD ($)
|
Dec. 31, 2013
USD ($)
|
Dec. 31, 2012
USD ($)
|
Dec. 31, 2011
USD ($)
|
Dec. 31, 2013
USD ($)
|
Jan. 07, 2011
Asphelia Asset Purchase [Member]
USD ($)
|
Dec. 31, 2013
Asphelia Asset Purchase [Member]
USD ($)
|
Apr. 30, 2012
Falk [Member]
USD ($)
|
Apr. 30, 2012
Falk [Member]
EUR (€)
|
Mar. 31, 2012
Falk [Member]
USD ($)
|
Mar. 31, 2012
Falk [Member]
EUR (€)
|
Dec. 31, 2013
Falk [Member]
USD ($)
|
Dec. 31, 2013
Falk [Member]
EUR (€)
|
Nov. 30, 2007
UCLB [Member]
USD ($)
|
Mar. 31, 2012
UCLB [Member]
USD ($)
|
Dec. 31, 2013
UCLB [Member]
|
Dec. 31, 2013
UCLB [Member]
Minimum [Member]
|
Dec. 31, 2013
UCLB [Member]
Maximum [Member]
|
Dec. 31, 2010
Burnham [Member]
USD ($)
|
Jan. 07, 2011
Ovamed [Member]
USD ($)
|
Dec. 31, 2013
Ovamed [Member]
USD ($)
|
Dec. 31, 2012
Ovamed [Member]
USD ($)
|
Feb. 22, 2013
FU Berlin [Member]
USD ($)
|
Feb. 22, 2013
FU Berlin [Member]
EUR (€)
|
Dec. 31, 2013
FU Berlin [Member]
USD ($)
|
Feb. 22, 2013
FU Berlin [Member]
Joint Ownership and Exclusive License Agreement [Member]
USD ($)
|
Feb. 22, 2013
FU Berlin [Member]
Joint Ownership and Exclusive License Agreement [Member]
EUR (€)
|
Feb. 22, 2013
FU Berlin [Member]
License and Sublicense Agreement [Member]
EUR (€)
|
|
| Business Acquisition [Line Items] | ||||||||||||||||||||||||||||
| Date of acquisition | Jan. 07, 2011 | |||||||||||||||||||||||||||
| Payment for purchase of assets | $ 20,706,000 | |||||||||||||||||||||||||||
| Number of Series B Shares issued | 2,525,677 | |||||||||||||||||||||||||||
| Series B Convertible Preferred Stock issued, per share | $ 6.38 | |||||||||||||||||||||||||||
| PCP Note, principal amount | 750,000 | |||||||||||||||||||||||||||
| Cash paid for asset purchase | 3,809,000 | |||||||||||||||||||||||||||
| Payment to related party | 61,000 | 3,400,000 | ||||||||||||||||||||||||||
| Repayment of Asphelias debt | 400,000 | |||||||||||||||||||||||||||
| Acquired in-process research and development | 0 | 1,043,000 | 20,706,000 | 21,749,000 | 20,700,000 | |||||||||||||||||||||||
| Contingent milestone payments to OvaMed | 5,450,000 | |||||||||||||||||||||||||||
| Milestone payments to related party | 1,400,000 | 1,000,000 | 1,500,000 | |||||||||||||||||||||||||
| Cash paid to Falk | 6,500,000 | 5,000,000 | ||||||||||||||||||||||||||
| Royalty payable to Falk | 1.00% | 1.00% | ||||||||||||||||||||||||||
| Additional payments to Falk | 2,000,000 | 1,500,000 | ||||||||||||||||||||||||||
| Remaining amount payable to Falk | 3,400,000 | 2,500,000 | ||||||||||||||||||||||||||
| Percentage responsibility for clinical testing | 50.00% | 50.00% | ||||||||||||||||||||||||||
| Total amount paid for purchase of manufacturing agreement | 1,500,000 | |||||||||||||||||||||||||||
| Related Party Transaction Equal Installment Amount | 500,000 | |||||||||||||||||||||||||||
| Property Lease Period | 5 years | |||||||||||||||||||||||||||
| Net present value | 1,000,000 | |||||||||||||||||||||||||||
| Upfront payment for license | 100,000 | |||||||||||||||||||||||||||
| Future milestone payment | 22,000,000 | |||||||||||||||||||||||||||
| Recognition of milestone payment | 250,000 | |||||||||||||||||||||||||||
| Royalty Percentage | 3.00% | 5.00% | ||||||||||||||||||||||||||
| Agreement termination notice period | 30 days | |||||||||||||||||||||||||||
| Upfront fee for amendment of license | 50,000 | |||||||||||||||||||||||||||
| Additional upfront fee for amendment of license | 25,000 | |||||||||||||||||||||||||||
| Management fee right to reduce transfer fee component agreed days | 10 days | |||||||||||||||||||||||||||
| Management fee right to reduce transfer fee component additional amount agreed days | 90 days | |||||||||||||||||||||||||||
| Potential Net Sales Of Products Ranging Minimum | 1.00% | 1.00% | 1.00% | |||||||||||||||||||||||||
| Potential Net Sales Of Products Ranging Maximum | 2.50% | 2.50% | 2.50% | |||||||||||||||||||||||||
| Research and development expense | $ 25,682,000 | $ 17,468,000 | $ 8,583,000 | $ 67,691,000 | $ 853,000 | € 648,000 | $ 183,000 | $ 4,982,000 | € 3,830,000 | € 1,025,000 | ||||||||||||||||||
| Letter Agreement Description | The Letter Agreement provides that Ovamed will retain a 10% interest in FU Berlins rights to the Joint Intellectual Property in the Ovamed Territory. | The Letter Agreement provides that Ovamed will retain a 10% interest in FU Berlins rights to the Joint Intellectual Property in the Ovamed Territory. | ||||||||||||||||||||||||||